Aimmune Therapeutics, maker of peanut allergy treatment, will be acquired by Nestle

Aimmune Therapeutics, maker of a peanut allergy treatment, said Monday that it will be acquired by the food conglomerate Nestle, which is seeking to expand its health sciences unit.

The all-cash deal values Aimmune at $2.6 billion, or $34.50 per share. Aimmune shares closed Friday at $12.60, near a four-year low due to the company’s struggles to launch its Palforzia peanut allergy treatment during the coronavirus pandemic.

Nestle already owned about 25% of Aimmune going into Monday’s deal. Aimmune will be folded into Nestle’s health sciences unit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In